Parecoxib

For the "dynastat" type of hybrid airship, see Hybrid airship.
Parecoxib
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • AU: C
Routes of
administration		Intravenous, intramuscular
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances)[1]
  • UK: POM (Prescription only)
  • EU: Rx-only[2]
Pharmacokinetic data
Bioavailability100%
Protein binding98%
MetabolismLiver to valdecoxib and propionic acid
CYP extensively involved (mainly CYP3A4 and 2C9)
Elimination half-life22 minutes (parecoxib)
8 hours (valdecoxib)
ExcretionKidney (70%, metabolites)
Identifiers
  • N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]
    sulfonyl}propanamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.230.078 Edit this at Wikidata
Chemical and physical data
FormulaC19H18N2O4S
Molar mass370.42 g·mol−1
3D model (JSmol)
  • O=C(NS(=O)(=O)c3ccc(c2c(onc2c1ccccc1)C)cc3)CC
  • InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) checkY
  • Key:TZRHLKRLEZJVIJ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Parecoxib, sold under the brand name Dynastat among others, is a water-soluble and injectable prodrug of valdecoxib. Parecoxib is a COX2 selective inhibitor. It is injectable. It is approved in the European Union for short term perioperative pain control.

It was patented in 1996 and approved for medical use in 2002.[3]

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Dynastat EPAR". European Medicines Agency. 22 March 2002. Retrieved 2 January 2024.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 9783527607495.